Elderly lung cancer patients: What treatment strategies?

Expert Review of Anticancer Therapy

Volumn 7, Issue 10, 2007, Pages 1331-1334

  Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; SORAFENIB; SUNITINIB; VANDETANIB;

ADJUVANT THERAPY; ADVANCED CANCER; AGED; AGING; ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER MORTALITY; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DRUG CONTRAINDICATION; EDITORIAL; ELDERLY CARE; HEMOPTYSIS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PATIENT SELECTION; PHENOTYPE; QUALITY OF LIFE; UNSPECIFIED SIDE EFFECT; DISEASE MANAGEMENT; FEMALE; LIFE EXPECTANCY; LUNG TUMOR; MALE; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY;

AGED; AGING; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; FEMALE; HUMANS; LIFE EXPECTANCY; LUNG NEOPLASMS; MALE; PATIENT SELECTION; QUALITY OF LIFE;

EID: 35848934994     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.10.1331     Document Type: Editorial

References (26)

1. Yancik R, Ries L. Cancer in older persons: an international issue in an aging world. Semin. Oncul. 31(2), 128-136 (2004).
2. Extermann M. Interaction between comorbidity and cancer. Cancer Control 14(1), 13-22 (2007).
3. Anisimov VN. Biology of aging and cancer. Cancer Control 14(1), 23-31 (2007).
4. Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Aibain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341(27), 2061-2067, (1999).
5. Talarico L, Chen G, Pazdur R. Enrolment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J. Clin. Oncol. 22(22), 4626-4631 (2004).
6. Balducci L. Geriatric oncology: challenges for the new century. Eur. J. Cancer 36 (14), 1741-1754 (2000).
7. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J. Clin. Oncol. 16(4), 1582-1587 (1998).
8. Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J. 11(6), 449-460 (2005).
9. Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J. 11(6), 461-473 (2005).
10. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 56(3), M146-M156 (2001).
11. Balducci L. Aging, frailty, and chemotherapy. Cancer Control 14(1), 7-12 (2007).
12. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
13. Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J. Clin. Oncol. 24(28), 4539-4544 (2006).
14. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer. J. Natl Cancer Inst. 91(1), 66-72 (1999).
15. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J. Natl Cancer Inst. 95(5), 362-372 (2003).
16. Kudoh S, Takeda K, Nakagawa K et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJOG 9904). J. Clin. Oncol. 24(22), 3657-3663 (2006).
17. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol. 22(2), 330-353 (2004).
18. Gridelli C, Aapro M, Ardizzoni A et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international export panel. J. Clin. Oncol. 23(13), 3125-3137 (2005).
19. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. 311(7010), 899-909 (1995).
20. Fruh M,Tribodet H,Pignon JP et al. A pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small cell lung cancer. J. Clin. Oncol. 25(Suppl. 18), S397 (2007) (Abstract 7553).
21. Pepe C, Hasan B, Winton TL et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J. Clin. Oncol. 25(12), 1553-1561 (2007).
22. Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer in the elderly. J. Clin. Oncol. 25(14), 1898-1907 (2007).
23. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl. J. Med. 353(2), 123-132 (2005).
24. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006). Erratum in: N Engl. J. Med. 356(3), 318 (2007).
25. Jackman D, Yeap YB, Lindeman IN et al. Phase II clinical trial of chemotherapy naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J. Clin. Oncol. 25(7), 760-766 (2007).
26. Ramalingam SS, Dahlberg SE, Langer CJ et al. Outcomes for elderly advanced stage non-small cell lung cancer (NSCLC) patients (pts) treated with bevacizumab (B) in combination with carboplatin (C) and paclitaxel (P): analysis of Eastern Cooperative Oncology Group (ECOG) 4599 study. J. Clin. Oncol. 25 (Suppl. 18), S393 (2007) (Abstract 7535).